Valuation
26% of the score, 30% here after data gaps
0median 56
An operating loss over the last year: there are no earnings to price.
HROWHarrow, Inc.
$31.60-21% 1Y
$31.60
$29.0352 weeks$54.80
RyuScore
Seven criteria, each scored 0 to 100 on a published scale, weighted into one number.
RyuScore 29 out of 100, Weak
Weak. Harrow, Inc. scores higher than 22% of the 1,794 companies Ryufin scores.
Carried by return on new capital and earnings quality, held back by valuation and return on capital.
Healthcare median 29 · all companies 57
How the score has moved
At each fiscal year end, from the reports and price of the time18
12
7
22
29
29
20202021202220242025today
The biggest move was up 15 points from 2022 to 2024, mostly return on new capital.
Return on capital
18% of the score, 20% here after data gaps
9median 34
Over 7 years the business earned 3.2% a year after tax on the capital it uses.
2%
8%
15%
25%
3.2%
None at 2% or less, full points from 25%full points
7 years agolatest 6.9%
Return on new capital
16% of the score, 18% here after data gaps
100median 49
For every dollar of operating profit earned over 6 years, yearly profit grew by 43 cents. New capital earned 4.6%, and 942% of profit went back into the business.
-5%
12%
43%
None at minus 5 cents, full points from 12 centsfull points
Capital allocation
14% of the score, 16% here after data gaps
16median 67
How management spends the money: shares bought back or issued, and whether assets grow faster than the business they serve.
Share countUp 7.3% a year over 5 years: new shares
05%
-3%
7.3%
0 pointsfull points
Assets against salesAssets grew 47% a year, sales 41%
4012%
-2%
6.4%
0 pointsfull points
Cycle position
Taken out: its 12% is shared by the others
n/ano data
Margins have been too thin to measure a cycle against.
Balance sheet
8% of the score, 9% here after data gaps
0median 50
What the debt weighs against the profit that has to carry it.
Net debt to EBITDA53.7x a year of EBITDA
04.5x
0.5x
53.7x
0 pointsfull points
Interest coverAn operating loss: the interest is not covered
01.5x
12x
-0.1x
0 pointsfull points
Earnings quality
6% of the score, 7% here after data gaps
100median 90
Whether the reported profit arrives as cash, and whether the accounts show the usual signs of stretching.
AccrualsCash ran ahead of profit by 12.4% of assets
1008%
0%
-8%
-12%
0 pointsfull points
Beneish M-scoreTaken out: sales grew 36% in a year, and the model flags that much growth on its own
n/aHow the RyuScore works
Each criterion earns 0 to 100 points on the scale drawn under it, and the RyuScore is their average weighted 26, 18, 16, 14, 12, 8 and 6. Scales bend in the company's favour between their ends, so an ordinary figure is never already near zero. For HROW, cycle position could not be measured from the filings, so it is taken out and the remaining weights scale up.
Built from the company's annual and quarterly filings with the SEC and today's share price. Banks, insurers and property trusts are not scored: their debt is their raw material, so these yardsticks mean something else there. Figures as of 2026-06-30, latest annual report FY2025.
On our screens:Most shorted stocks
Drug Manufacturers, Specialty & Generic
Ranks #18 of 29 by RyuScore